Article

Biomarkers Identify Patients at Risk for Hip Replacement Failure

Urinary markers may predict the development of osteolysis following total hip replacement.

Image credit: ©ChooChin/Shutterstock.com

Urinary markers may predict the development of osteolysis in patients who have undergone total hip replacement, according to researchers at Rush University Medical Center in Chicago. Their findings are published in the Journal of Orthopaedic Research.

For the study, researchers used a repository of 24-hour urine samples collected before surgery and annually thereafter in 26 patients. Osteolysis eventually developed in 16 of these patients.

The levels of certain markers helped the investigators identify patients at risk for osteolysis long before the emergence of radiographic signs-in some cases, 6 years before a diagnosis was made. Although single markers showed moderate accuracy, the combination of α-crosslaps (α-CTX), a bone resorption marker, and interleukin‐6 (IL‐6), an inflammatory marker, led to high accuracy in the differentiation of patients who eventually developed osteolysis from those with no signs of osteolysis.

“We are hopeful that early biomarkers for implant loosening will alert surgeons to be especially vigilant in their follow-up of at-risk patients and may eventually lead to treatments delaying or avoiding the need for revision surgery,” said senior author Dr. D. Rick Sumner, of Rush University Medical Center. “Perhaps even more intriguing is that the two biomarkers we identified also differed before surgery among patients who eventually developed peri-implant osteolysis and those who did not, supporting the concept that other researchers have proposed of genetic risk factors for loosening.”

References:

Ross RD, Deng Y, Fang R, et al. Discovery of biomarkers to identify peri-implant osteolysis before radiographic diagnosis. J Orthop Res. 2018 Jun 5. doi: 10.1002/jor.24044. [Epub ahead of print]

Urinary markers predict bone problems after hip replacement [press release]. Hoboken, NJ: John Wiley & Sons, Inc.; June 6, 2018.

Related Videos
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
© 2024 MJH Life Sciences

All rights reserved.